Akèy › Kansè nan tete › New Mexico
Etid klinik pou Kansè nan tete nan New Mexico
19 etid pou Kansè nan tete ap chèche patisipan nan sit nan New Mexico.
Vil nan New Mexico
Tèks ofisyèl etid la (Anglè)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Presbyterian Medical Group, Albuquerque
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Oct 2, 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Lovelace Medical Center-Saint Joseph Square, Albuquerque
- University of New Mexico Cancer Center, Albuquerque
- Lovelace Women's Hospital, Albuquerque
- ak 3 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- The University of New Mexico, Albuquerque
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07102381A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Presbyterian Kaseman Hospital ( Site 0072), Albuquerque
- University of New Mexico Comprehensive Cancer Center ( Site 0047), Albuquerque
- Presbyterian Rust Jorgensen Cancer ( Site 0073), Rio Rancho
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07060807The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Lovelace Medical Center - Saint Joseph Square, Albuquerque
- Lovelace Women's Hospital, Albuquerque
- Presbyterian Kaseman Hospital, Albuquerque
- ak 3 plis
Ap rekriteFaz 3
Laj 60 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06377852A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Albuquerque
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06103864Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Santa Fe
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- New Mexico Oncology & Hematology Consultants, Albuquerque
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07214532A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Exigent Research LLC/New Mexico Oncology Hematology Consultants Ltd., Albuquerque
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06492616A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Albuquerque
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT05123482A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- San Juan Oncology Associates, Farmington
Ap rekriteFaz 1
Laj 18 a 55 · Fanm · Mizajou Sep 9, 2026 · NCT07310420Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- University of New Mexico Cancer Center, Albuquerque
- Presbyterian Kaseman Hospital, Albuquerque
- Memorial Medical Center-Las Cruces, Las Cruces
- ak 1 plis
Ap rekriteFaz 3
Laj 18 a 60 · Fanm · Mizajou Sep 2, 2026 · NCT05879926Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Presbyterian Kaseman Hospital, Albuquerque
- Presbyterian Rust Cancer Center, Rio Rancho
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jun 22, 2026 · NCT05696626De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- University of New Mexico Cancer Center, Albuquerque
Ap rekriteFaz 3
Laj 50 a 70 · Tout sèks · Mizajou Apr 23, 2026 · NCT04852887SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
- University of New Mexico, Albuquerque
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Apr 7, 2026 · NCT06896474Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Lovelace Medical Center-Saint Joseph Square, Albuquerque
- University of New Mexico Cancer Center, Albuquerque
- Lovelace Women's Hospital, Albuquerque
- ak 3 plis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 17, 2026 · NCT06418204SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Albuquerque
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- University of New Mexico Cancer Center, Albuquerque
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 8, 2025 · NCT03418961BostonGene and Exigent Genomic INsight Study
- New Mexico Cancer Center, Albuquerque
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Feb 17, 2025 · NCT06272864Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.